Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a phase 2, open-label, randomized, multicenter clinical trial in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) who meet the criteria for standard-of-care FDA label for CD19 CAR T-cell therapy with brexucabtagene autoleucel (brexu-cel).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona diagnoża chłoniaka typu płaszcza
- •Wiek co najmniej 18 lat
- •Zdolność do zrozumienia i podpisania zgody na uczestnictwo w badaniu
- •Kwalifikacja do terapii komórkami CAR-T zgodnie ze standardami medycznymi
- •Dobry stan ogólny zdrowia (skala ECOG 0-2)
- •Przerwy w poprzednim leczeniu (od 5 dni do 3 miesięcy w zależności od rodzaju leczenia)
- •Dla kobiet i mężczyzn: zgoda na używanie antykoncepcji podczas badania
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 23, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Stanford Cancer Center
Stanford, United States
Univ of Miami - Sylvester Comprehensive Cancer Center
Miami, United States
Moffitt Cancer Center
Tampa, United States
Trial contact
Ruthie Chae
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/24/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.